Cargando…

DZIP1 Expression as a Prognostic Marker in Gastric Cancer: A Bioinformatics-Based Analysis

PURPOSE: Gastric cancer (GC) is a common type of cancer worldwide. It can relapse and metastasize even after standard treatment; therefore, it has a poor prognosis. Moreover, sensitive biomarkers for prognosis prediction in GC are lacking. In this study, using a bioinformatics approach, we aimed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yuan-Jie, Li, Jie-Pin, Zeng, Shu-Hong, Han, Mei, Liu, Shen-Lin, Zou, Xi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453447/
https://www.ncbi.nlm.nih.gov/pubmed/34557018
http://dx.doi.org/10.2147/PGPM.S325701
_version_ 1784570273690812416
author Liu, Yuan-Jie
Li, Jie-Pin
Zeng, Shu-Hong
Han, Mei
Liu, Shen-Lin
Zou, Xi
author_facet Liu, Yuan-Jie
Li, Jie-Pin
Zeng, Shu-Hong
Han, Mei
Liu, Shen-Lin
Zou, Xi
author_sort Liu, Yuan-Jie
collection PubMed
description PURPOSE: Gastric cancer (GC) is a common type of cancer worldwide. It can relapse and metastasize even after standard treatment; therefore, it has a poor prognosis. Moreover, sensitive biomarkers for prognosis prediction in GC are lacking. In this study, using a bioinformatics approach, we aimed to examine the value of DAZ Interacting Protein 1 (DZIP1) as a prognostic predictor and therapeutic target in GC. METHODS: We explored the clinical relevance, function, and molecular role of DZIP1 in GC using MethSurv, cBioPortal, TIMER, Gene Expression Profiling Interactive Analysis, IMEx, ONCOMINE, MEXPRESS, and EWAS Atlas databases. The GSE118919 dataset was used to plot receiver operating characteristic curves. Using The Cancer Genome Atlas, we developed a Cox regression model and assessed the clinical significance of DZIPs. In addition, we used the “xCELL” algorithm to make reliable immune infiltration estimations. Western blot and immunohistochemistry were used to examine protein expression. The results were visualized with the ‘ggplot2ʹ and “circlize” packages. RESULTS: In GC patients, DZIP1 was over-expressed at both the mRNA and protein levels. High levels of DZIP1 were found to be associated with poor survival in patients with GC. Our results indicated that DZIP1 could be involved in multiple cancer-related pathways such as the PI3K-Akt signaling pathway, WNT signaling pathway, and RAS signaling pathway, and its expression was correlated with the infiltration of activated myeloid dendritic cells, naive CD4+ T cells, and naive CD8+ T cells. Furthermore, we found that mutations in DZIP1 were correlated with a good prognosis in GC patients. Finally, we demonstrated a correlation between hypomethylation of the DZIP1 gene promoter and a poor prognosis in GC. CONCLUSION: This study is the first to demonstrate a significant correlation between high levels of DZIP1 and a poor prognosis in GC patients. Our results clarify multiple potential mechanisms that could contribute to this correlation and may thus provide novel insights into the clinical diagnosis and treatment of GC.
format Online
Article
Text
id pubmed-8453447
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-84534472021-09-22 DZIP1 Expression as a Prognostic Marker in Gastric Cancer: A Bioinformatics-Based Analysis Liu, Yuan-Jie Li, Jie-Pin Zeng, Shu-Hong Han, Mei Liu, Shen-Lin Zou, Xi Pharmgenomics Pers Med Original Research PURPOSE: Gastric cancer (GC) is a common type of cancer worldwide. It can relapse and metastasize even after standard treatment; therefore, it has a poor prognosis. Moreover, sensitive biomarkers for prognosis prediction in GC are lacking. In this study, using a bioinformatics approach, we aimed to examine the value of DAZ Interacting Protein 1 (DZIP1) as a prognostic predictor and therapeutic target in GC. METHODS: We explored the clinical relevance, function, and molecular role of DZIP1 in GC using MethSurv, cBioPortal, TIMER, Gene Expression Profiling Interactive Analysis, IMEx, ONCOMINE, MEXPRESS, and EWAS Atlas databases. The GSE118919 dataset was used to plot receiver operating characteristic curves. Using The Cancer Genome Atlas, we developed a Cox regression model and assessed the clinical significance of DZIPs. In addition, we used the “xCELL” algorithm to make reliable immune infiltration estimations. Western blot and immunohistochemistry were used to examine protein expression. The results were visualized with the ‘ggplot2ʹ and “circlize” packages. RESULTS: In GC patients, DZIP1 was over-expressed at both the mRNA and protein levels. High levels of DZIP1 were found to be associated with poor survival in patients with GC. Our results indicated that DZIP1 could be involved in multiple cancer-related pathways such as the PI3K-Akt signaling pathway, WNT signaling pathway, and RAS signaling pathway, and its expression was correlated with the infiltration of activated myeloid dendritic cells, naive CD4+ T cells, and naive CD8+ T cells. Furthermore, we found that mutations in DZIP1 were correlated with a good prognosis in GC patients. Finally, we demonstrated a correlation between hypomethylation of the DZIP1 gene promoter and a poor prognosis in GC. CONCLUSION: This study is the first to demonstrate a significant correlation between high levels of DZIP1 and a poor prognosis in GC patients. Our results clarify multiple potential mechanisms that could contribute to this correlation and may thus provide novel insights into the clinical diagnosis and treatment of GC. Dove 2021-09-16 /pmc/articles/PMC8453447/ /pubmed/34557018 http://dx.doi.org/10.2147/PGPM.S325701 Text en © 2021 Liu et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Liu, Yuan-Jie
Li, Jie-Pin
Zeng, Shu-Hong
Han, Mei
Liu, Shen-Lin
Zou, Xi
DZIP1 Expression as a Prognostic Marker in Gastric Cancer: A Bioinformatics-Based Analysis
title DZIP1 Expression as a Prognostic Marker in Gastric Cancer: A Bioinformatics-Based Analysis
title_full DZIP1 Expression as a Prognostic Marker in Gastric Cancer: A Bioinformatics-Based Analysis
title_fullStr DZIP1 Expression as a Prognostic Marker in Gastric Cancer: A Bioinformatics-Based Analysis
title_full_unstemmed DZIP1 Expression as a Prognostic Marker in Gastric Cancer: A Bioinformatics-Based Analysis
title_short DZIP1 Expression as a Prognostic Marker in Gastric Cancer: A Bioinformatics-Based Analysis
title_sort dzip1 expression as a prognostic marker in gastric cancer: a bioinformatics-based analysis
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453447/
https://www.ncbi.nlm.nih.gov/pubmed/34557018
http://dx.doi.org/10.2147/PGPM.S325701
work_keys_str_mv AT liuyuanjie dzip1expressionasaprognosticmarkeringastriccancerabioinformaticsbasedanalysis
AT lijiepin dzip1expressionasaprognosticmarkeringastriccancerabioinformaticsbasedanalysis
AT zengshuhong dzip1expressionasaprognosticmarkeringastriccancerabioinformaticsbasedanalysis
AT hanmei dzip1expressionasaprognosticmarkeringastriccancerabioinformaticsbasedanalysis
AT liushenlin dzip1expressionasaprognosticmarkeringastriccancerabioinformaticsbasedanalysis
AT zouxi dzip1expressionasaprognosticmarkeringastriccancerabioinformaticsbasedanalysis